Silverarc Capital Management, LLC Poseida Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

$298 Million
Q1 2024

A detailed history of Silverarc Capital Management, LLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 3,596,476 shares of PSTX stock, worth $10.5 Million. This represents 3.85% of its overall portfolio holdings.

Number of Shares

3,596,476

Previous 3,705,779 2.95%

Holding current value

$10.5 Million

Previous $12.5 Million 7.86%

% of portfolio

3.85%

Previous 3.94%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.76 - $4.13 $301,676 - $451,421	-109,303 Reduced 2.95%	3,596,476 $11.5 Million
Q4 2023 Feb 14, 2024	BUY	$1.83 - $3.51 $252,163 - $483,656	137,794 Added 3.86%	3,705,779 $12.5 Million
Q3 2023 Nov 13, 2023	BUY	$1.62 - $2.79 $1.01 Million - $1.74 Million	622,037 Added 21.12%	3,567,985 $8.49 Million
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $426,034 - $872,599	256,647 Added 9.54%	2,945,948 $5.18 Million
Q1 2023 May 15, 2023	BUY	$3.08 - $8.73 $1.41 Million - $4.01 Million	459,301 Added 20.6%	2,689,301 $8.28 Million

Q4 2022 Feb 14, 2023	SELL	$4.04 - $6.38 $1.31 Million - $2.07 Million	-324,277 Reduced 12.7%	2,230,000 $11.8 Million
Q3 2022 Oct 28, 2022	BUY	$2.43 - $4.51 $5.28 Million - $9.8 Million	2,173,671 Added 571.11%	2,554,277 $9.02 Million
Q2 2022 Jul 25, 2022	BUY	$1.87 - $5.0 $263,501 - $704,550	140,910 Added 58.79%	380,606 $982,000
Q1 2022 May 13, 2022	BUY	$3.22 - $7.04 $15,340 - $33,538	4,764 Added 2.03%	239,696 $1.07 Million
Q4 2021 Feb 14, 2022	BUY	$6.23 - $7.6 $1.46 Million - $1.79 Million	234,932 New	234,932 $1.6 Million

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.1M

Call Options Held

255K

Put Options Held

62K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $250M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.

Account

Silverarc Capital Management, LLC Poseida Therapeutics, Inc. Transaction History